Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry
暂无分享,去创建一个
S. Fox | G. Giles | J. Hopper | E. John | M. Southey | S. Buys | I. Andrulis | A. Mulligan | A. Godwin | F. O'Malley | Letitia D Smith | H. Ozçelik | R. Santella | M. Daly | D. Goldgar | M. Terry | R. Senie | S. Ramus | E. Wong | A. Tesoriero | Letitia D. Smith
[1] M. Southey,et al. Morphological predictors of BRCA1 germline mutations in young women with breast cancer , 2011, British Journal of Cancer.
[2] T. Byers,et al. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. , 2010, Cancer research.
[3] T. Rebbeck,et al. Incorporating tumour pathology information into breast cancer risk prediction algorithms , 2010, Breast Cancer Research.
[4] M. Zikan,et al. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene , 2010, Breast Cancer Research and Treatment.
[5] A. Whittemore,et al. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research , 2009, Breast Cancer Research and Treatment.
[6] P. Nederlof,et al. Deletion of exons 1a-2 of BRCA1: a rather frequent pathogenic abnormality. , 2009, Genetic Testing and Molecular Biomarkers.
[7] Alun Thomas,et al. Classification of rare missense substitutions, using risk surfaces, with genetic‐ and molecular‐epidemiology applications , 2008, Human mutation.
[8] S. Tavtigian,et al. In silico analysis of missense substitutions using sequence‐alignment based methods , 2008, Human mutation.
[9] H A Risch,et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.
[10] G. Giles,et al. BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study. , 2007, European journal of cancer.
[11] A. Whittemore,et al. Population‐based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066–6T>G (IVS10–6T>G) from the Breast Cancer Family Registry , 2006, Human mutation.
[12] M. Federico,et al. Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations , 2006, Genes, chromosomes & cancer.
[13] B. Mukesh,et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Hanina Hibshoosh,et al. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study , 2006, Modern Pathology.
[15] L. Chieco‐Bianchi,et al. Large genomic deletions inactivate the BRCA2 gene in breast cancer families , 2005, Journal of Medical Genetics.
[16] Norman Boyd,et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.
[17] N. Boyd,et al. Individual and family characteristics associated with protein truncating BRCA1 and BRCA2 mutations in an Ontario population based series from the Cooperative Family Registry for Breast Cancer Studies , 2003, Journal of medical genetics.
[18] L. V. van't Veer,et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. , 2003, Cancer research.
[19] John L Hopper,et al. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. , 2003, Journal of the National Cancer Institute.
[20] A. Whittemore,et al. Comparison of DNA‐ and RNA‐Based Methods for Detection of Truncating BRCA1 Mutations , 2002, Human mutation.
[21] D. Zwijnenburg,et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.
[22] M. J. van de Vijver,et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Sambrook,et al. Dominant negative ATM mutations in breast cancer families. , 2002, Journal of the National Cancer Institute.
[24] M. Southey,et al. Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients. , 2000, International journal of radiation oncology, biology, physics.
[25] G. Giles,et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[26] G. Giles,et al. BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer , 1999, British Journal of Cancer.
[27] G. Giles,et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations , 1998, Cancer.
[28] M. Stratton,et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.
[29] Peter Devilee,et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients , 1997, Nature Genetics.
[30] E. V. Rensburg,et al. Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation , 2010, Breast Cancer Research and Treatment.